The Impact of GLP ‐1‐Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta‐Analysis
Authors' conclusion
GLP-1-based therapies were associated with an overall favourable cardiovascular profile in T2DM. Pairwise analyses supported class-level benefit, whereas between-agent differences were more evident for MACE than for mortality outcomes in the NMA.
Study context
- Population
- Adults with T2D in RCTs reporting time-to-event cardiovascular outcomes; PubMed, Cochrane Library and Scopus searched through December 2025
- Participants
- 97,173 adults15 trials
- Comparison
- GLP-1-based therapies vs placebo and between agents
- Outcome
- All-cause mortality, cardiovascular mortality and MACE (pairwise placebo-controlled analyses)
Methodological detailsfrequentist random-effects network meta-analysis (NMA), pairwise meta-analyses, HR-based
- Frequentist random-effects NMA
- Pairwise meta-analyses
- HR-based
Pooled result
As reported in the abstract
- GLP-1-based therapies significantly reduced all-cause mortality, cardiovascular mortality and major adverse cardiovascular events (MACE) vs placebo
Further pooled results
Mortality (NMA)
- Estimates for several agents favoured benefit, although most comparisons were not statistically significant
MACE (NMA)
- Efpeglenatide, albiglutide and injectable semaglutide showed the most favourable comparative profiles
Non-fatal myocardial infarction (MI) and non-fatal stroke (NMA)
- Albiglutide reduced non-fatal MI vs placebo
- Non-fatal stroke estimates were imprecise
Original publication
The Impact of GLP ‐1‐Based Therapies on Cardiovascular Outcomes in Type 2 Diabetes: A Comprehensive Systematic Review and Network Meta‐Analysis. Diabetes Obes Metab. Published 31 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →